Vancouver, British Columbia–(Newsfile Corp. – August 25, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College’s Center for Psychedelic Research…
